MRNA:OTCQB-Marina Biotech Inc (USD)

COMMON STOCK | Biotechnology | OTCQB - U.S. Registered

Last Closing

USD 117.44

Change

+1.37 (+1.18)%

Market Cap

USD 0.02B

Volume

2.82M

Analyst Target

USD 89.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Marina Biotech Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-6.88 (-1.37%)

USD 126.85B
REGN Regeneron Pharmaceuticals Inc

+1.39 (+0.13%)

USD 117.19B
ARGX argenx NV ADR

+6.66 (+1.31%)

USD 30.45B
ALNY Alnylam Pharmaceuticals Inc

+3.65 (+1.56%)

USD 29.58B
BGNE BeiGene Ltd

+9.60 (+6.12%)

USD 16.93B
RPRX Royalty Pharma Plc

-0.37 (-1.30%)

USD 16.81B
BMRN Biomarin Pharmaceutical Inc

-0.06 (-0.07%)

USD 15.97B
UTHR United Therapeutics Corporatio..

-24.25 (-7.18%)

USD 14.60B
SRPT Sarepta Therapeutics Inc

-0.80 (-0.56%)

USD 13.76B
INCY Incyte Corporation

-2.72 (-4.01%)

USD 12.98B

ETFs Containing MRNA

XT iShares Exponential Techn.. 1,000.00 % 0.47 %

+1.39 (+0.82%)

N/A
MRN3:LSE Leverage Shares 3x Long M.. 300.12 % 0.00 %

+0.10 (+0.82%)

USD 0.37M
MSGR 6.26 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 5.80 % 0.00 %

+0.13 (+0.82%)

USD 7.04M
CURE:XETRA VanEck Genomics and Healt.. 5.70 % 0.00 %

+0.18 (+0.82%)

N/A
HVAX:CA 4.95 % 0.00 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 4.67 % 0.00 %

N/A

USD 0.52B
BTEC:SW iShares Nasdaq US Biotech.. 4.67 % 0.00 %

-0.03 (0.82%)

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 4.46 % 0.00 %

+0.03 (+0.82%)

USD 0.52B
GN0M:XETRA Global X Genomics & Biote.. 4.17 % 0.00 %

+0.04 (+0.82%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.17 % 0.00 %

-0.07 (0.82%)

USD 5.83M
GNOG:LSE Global X Genomics & Biote.. 3.80 % 0.00 %

+0.05 (+0.82%)

USD 6.19M
BTEC Principal Healthcare Inno.. 3.45 % 0.42 %

+0.40 (+0.82%)

USD 0.02B
XNNV:XETRA Xtrackers MSCI Innovation.. 3.03 % 0.00 %

+0.77 (+0.82%)

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

+0.62 (+0.82%)

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

+0.84 (+0.82%)

N/A
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.69 % 0.00 %

+0.11 (+0.82%)

N/A
MEDTE:PA BNP Paribas Easy ECPI Glo.. 2.69 % 0.00 %

+0.14 (+0.82%)

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.69 % 0.00 %

+0.07 (+0.82%)

N/A
ZUH:CA BMO Equal Weight US Healt.. 2.10 % 0.39 %

-0.33 (0.82%)

CAD 0.27B
FCTR 1.68 % 0.00 %

N/A

N/A
TAEQ 1.46 % 0.00 %

N/A

N/A
WEBA:XETRA Amundi US Tech 100 Equal .. 1.17 % 0.00 %

+0.21 (+0.82%)

USD 0.60B
QUS:AU BetaShares S&P 500 Equal .. 0.30 % 0.00 %

+0.93 (+0.82%)

USD 1.29B
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

+0.06 (+0.82%)

USD 1.47B
BBH VanEck Biotech ETF 0.00 % 0.35 %

+0.02 (+0.82%)

USD 0.44B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-0.24 (0.82%)

USD 0.09B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+1.39 (+0.82%)

N/A
FLAG 0.00 % 1.52 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+0.09 (+0.82%)

USD 7.71B
ZHU:CA 0.00 % 0.00 %

N/A

N/A
LS:CA 0.00 % 2.21 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

+0.06 (+0.82%)

USD 0.09B
HWF:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.05 (+0.82%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.02 (+0.82%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+0.82%)

N/A
RYH 0.00 % 0.40 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
GERM ETFMG Treatments Testing .. 0.00 % 0.00 %

+0.09 (+0.82%)

USD 0.01B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

+0.02 (+0.82%)

USD 0.04B
MRNS:LSE -299.96 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.07% 74% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.07% 74% C 80% B-
Trailing 12 Months  
Capital Gain -6.73% 65% D 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.73% 65% D 46% F
Trailing 5 Years  
Capital Gain 727.04% 97% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 727.04% 97% N/A 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 127.84% 93% A 96% N/A
Dividend Return 127.84% 93% A 96% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 221.39% 12% F 7% C-
Risk Adjusted Return 57.75% 96% N/A 84% B
Market Capitalization 0.02B 100% F 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector